Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum

Update Il y a 4 ans
Reference: EUCTR2006-001270-24

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with ticilimumab


Inclusion criteria

  • Refractory meatstatic adenocarcinoma of the colon or rectum

Links